FDA Approves Durvalumab for Limited-Stage SCLC

Durvalumab was associated with a 27% reduction in the risk for death compared with placebo in the phase 3 ADRIATIC trial.
Medscape Medical News

source https://www.medscape.com/viewarticle/fda-approves-durvalumab-limited-stage-sclc-2024a1000mhg?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension

Heart Failure Care Outside of ICU Can Lower Cost